UNOS Approves RMTI Treatment Protocol for Patients with Hilar Cholangiocarinoma
RMTI’s protocol for treating patients with hilar cholangiocarcinoma (CCA) was approved by the UNOS Liver and Intestinal Organ Transplantation Committee on June 17, 2010, offering new hope for CCA patients who ordinarily would not qualify for transplantation.
RMTI’s protocol for treating patients with hilar cholangiocarcinoma (CCA) was approved by the UNOS Liver and Intestinal Organ Transplantation Committee on June 17, 2010, offering new hope for CCA patients who ordinarily would not qualify for transplantation.
Patients who meet protocol criteria will be eligible for priority on the UNOS liver transplant waiting list. Additionally, for every three months that patients continue to meet the criteria, their placement on the waiting list will increase in priority.
Hilar cholangiocarcinoma: Difficult to treat
Hilar cholangiocarcinoma is a condition in which tumors originate from the bile ducts outside the liver. These tumors are very difficult to treat and frequently cause symptoms in the later stages of the disease, when surgical resection is no longer an option.
While surgical resection — the removal of a portion of the liver — is considered the primary curative treatment for certain patients, the overall survival rate after five years ranges from only 20 percent to 40 percent. Furthermore, many patients who have hilar cholangiocarcinoma are unable to undergo surgery due to existing liver disease, the location of the tumor, or the tumor’s involvement with the blood vessels. Liver transplantation provides an option for those who would not qualify for surgery because of poor liver function.
Protocol expands post-transplant therapies
In order to improve post-transplant outcomes for CCA patients and to achieve results similar to those of liver transplant recipients with other chronic liver diseases — an average 5-year survival rate of 75 percent — interest has been focused on neoadjuvant or pre-surgical treatment options. These treatment protocols involve radiotherapy and chemotherapy in highly selected patients and have shown encouraging results. RMTI’s protocol combines the benefits of radiotherapy, chemotherapy, with liver transplantation as a hope for cure.
Besides enabling more patients to qualify for transplantation, we anticipate that this will further define the role of these treatment protocols and transplantation in this difficult patient group and provide improved long-term survival.
For more information, you may contact:
Dorothy Robinson, DNP
Email: dorothy.robinson@mountsinai.org
Marcello Facciuto, MD
Email: marcello.facciuto@mountsinai.org
Tel: 212-659-8239
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.
Mount Sinai Surgeons Perform First Heart-Liver-Kidney Transplants in New York State
May 20, 2025 View All Press Releases
Renowned Transplant Hepatologist John Bucuvalas, MD, Joins Mount Sinai Health System
May 16, 2018 View All Press Releases